Table 3.
Adjusted rates of clinical outcomes per 1000 person-years in strata defined by eGFR and urinary ACR
| eGFR (ml/min per 1.73 m2) | Outcome | PVD |
PCI or CABG |
CHF |
CVA/TIA |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal ACR | Mild ACR | Heavy ACR | Overall | Normal ACR | Mild ACR | Heavy ACR | Overall | Normal ACR | Mild ACR | Heavy ACR | Overall | Normal ACR | Mild ACR | Heavy ACR | Overall | ||
| ≥60 | Events (n) | 131 | 49 | 12 | 192 | 1096 | 365 | 98 | 1559 | 281 | 238 | 110 | 629 | 405 | 187 | 63 | 655 |
| People in cell (n) | 64, 146 | 14, 597 | 2805 | 81, 548 | 64, 146 | 14, 597 | 2805 | 81, 548 | 64, 146 | 14, 597 | 2805 | 81, 548 | 64, 146 | 14, 597 | 2805 | 81, 548 | |
| Adjusted rate | 0.5 | 0.6 | 0.8 | 0.5 | 5.0 | 6.1 | 8.2 | 5.3 | 1.1 | 2.6 | 5.5 | 1.5 | 1.8 | 2.7 | 4.7 | 2.1 | |
| 95% CI | 0.4 to 0.6 | 0.4 to 0.8 | 0.4 to 1.4 | 0.4 to 0.6 | 4.7 to 5.4 | 5.5 to 6.8 | 6.7 to 10.0 | 5.0 to 5.6 | 0.9 to 1.2 | 2.2 to 3.0 | 4.4 to 6.7 | 1.4 to 1.7 | 1.6 to 2.0 | 2.3 to 3.2 | 3.6 to 6.1 | 1.9 to 2.3 | |
| 45 to 59.9 | Events (n) | 62 | 26 | 12 | 100 | 278 | 117 | 56 | 451 | 174 | 186 | 88 | 448 | 149 | 105 | 48 | 302 |
| People in cell (n) | 10, 316 | 3520 | 1126 | 14, 962 | 10, 316 | 3520 | 1126 | 14, 962 | 10, 316 | 3520 | 1126 | 14, 962 | 10, 316 | 3520 | 1126 | 14, 962 | |
| Adjusted rate | 0.7 | 0.7 | 1.0 | 0.7 | 5.6 | 6.0 | 9.0 | 5.9 | 1.6 | 3.6 | 5.8 | 2.2 | 1.9 | 3.2 | 5.1 | 2.4 | |
| 95% CI | 0.5 to 0.9 | 0.4 to 1.1 | 0.6 to 1.9 | 0.5 to 0.9 | 4.9 to 6.4 | 4.9 to 7.2 | 6.9 to 11.8 | 5.3 to 6.5 | 1.3 to 1.9 | 3.0 to 4.4 | 4.6 to 7.3 | 1.9 to 2.6 | 1.6 to 2.3 | 2.6 to 4.0 | 3.7 to 6.9 | 2.1 to 2.7 | |
| 30 to 44.9 | Events (n) | 25 | 23 | 7 | 55 | 86 | 57 | 35 | 178 | 105 | 128 | 97 | 330 | 76 | 50 | 33 | 159 |
| People in cell (n) | 2474 | 1624 | 837 | 4935 | 2474 | 1624 | 837 | 4935 | 2474 | 1624 | 837 | 4935 | 2474 | 1624 | 837 | 4935 | |
| Adjusted rate | 0.8 | 1.0 | 0.7 | 0.8 | 6.7 | 6.4 | 7.5 | 6.5 | 2.4 | 4.1 | 6.9 | 3.1 | 2.9 | 2.8 | 4.1 | 2.8 | |
| 95% CI | 0.5 to 1.2 | 0.6 to 1.7 | 0.3 to 1.5 | 0.6 to 1.2 | 5.4 to 8.4 | 4.8 to 8.4 | 5.4 to 10.7 | 5.6 to 7.8 | 2.0 to 3.1 | 3.3 to 5.0 | 5.5 to 8.8 | 2.6 to 3.6 | 2.2 to 3.7 | 2.0 to 3.8 | 2.8 to 5.9 | 2.3 to 3.4 | |
| 15 to 29.9 | Events (n) | 3 | 8 | 9 | 20 | 9 | 8 | 13 | 30 | 37 | 62 | 49 | 148 | 9 | 16 | 16 | 41 |
| People in cell (n) | 344 | 476 | 436 | 1256 | 344 | 476 | 436 | 1256 | 344 | 476 | 436 | 1256 | 344 | 476 | 436 | 1256 | |
| Adjusted rate | 0.6 | 1.4 | 2.4 | 1.4 | 5.6 | 3.6 | 6.1 | 4.8 | 4.8 | 6.5 | 6.2 | 4.6 | 2.5 | 3.3 | 3.9 | 2.9 | |
| 95% CI | 0.2 to 2.0 | 0.7 to 3.1 | 1.2 to 4.9 | 0.8 to 2.3 | 2.9 to 10.8 | 1.8 to 7.2 | 3.5 to 10.7 | 3.3 to 7.0 | 3.4 to 6.8 | 4.8 to 8.7 | 4.5 to 8.6 | 3.7 to 5.7 | 1.2 to 4.8 | 1.9 to 5.5 | 2.3 to 6.7 | 2.0 to 4.1 | |
Adjusted for age; gender; diabetes; hypertension; socioeconomic status; and history of cancer, cerebrovascular disease, CHF, chronic pulmonary disease, dementia, diabetes with end-organ damage, diabetes without chronic complication, AIDS/HIV, metastatic solid tumor, myocardial infarction, mild liver disease, moderate or severe liver disease, paralysis, peptic ulcer disease, PVD, renal disease, or rheumatic disease. In this analysis, only urinary ACR was used to classify participants with respect to proteinuria: normal (ACR < 30 mg/g), mild (ACR 30 to 300 mg/g), or heavy (ACR > 300 mg/g). n = 102,701 The tests for linear trend across proteinuria categories were all significant at the P < 0.001 level except for PVD (P = 0.15). Tests for trend across eGFR categories were PVD, P = 0.01; PCI or CABG, P = 0.01; CHF, P < 0.001; and CVA/TIA, P < 0.007.